|
|
Article: Miravant's SnET2 Positively Impacts the Disease Process in Macular Degeneration Patients; Phase III Clinical Results Presented at Key Ophthalmology Conference.
- Article from:
- Business Wire
- Article date:
- April 27, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
SANTA BARBARA, Calif.--(BUSINESS WIRE)--April 27, 2004
Miravant Medical Technologies (OTCBB: MRVT), a pharmaceutical development company specializing in PhotoPoint(R) photodynamic therapy (PDT), today announced that investigational drug SnET2 provided a visual acuity benefit and slowed the progression of problematic neovascular lesions in two independent phase III clinical trials of patients with wet age-related macular degeneration (AMD). The clinical results were presented by SnET2 clinical investigators at the Association for Research in Vision and Ophthalmology (ARVO) meeting, Ft. Lauderdale. In March 2004, ...